Development and Research Progress of Anti-Drug Resistant Bacteria Drugs

References

• Bennett JW, Chung KT. Alexander Fleming and the discovery of penicillin. Adv Appl Microbiol. 2001;49:163–184.11757350
   PubMed Web of Science ®Google Scholar
• Katz L, Baltz RH. Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol. 2016;43(2–3):155–176. doi:10.1007/s10295-015-1723-526739136
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433. doi:10.1128/MMBR.00016-1020805405
   PubMed Web of Science ®Google Scholar
• Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72–80. doi:10.1016/j.mib.2019.10.00831733401
   PubMed Web of Science ®Google Scholar
• Power E. Impact of antibiotic restrictions: the pharmaceutical perspective. Clin Microbiol Infect. 2006;12(Suppl 5):25–34. doi:10.1111/j.1469-0691.2006.01528.x
   PubMed Web of Science ®Google Scholar
• Wetzel C, Lonneman M, Wu C. Polypharmacological drug actions of recently FDA approved antibiotics. Eur J Med Chem. 2021;209:112931. doi:10.1016/j.ejmech.2020.11293133127170
   PubMed Web of Science ®Google Scholar
• Christaki E, Marcou M, Tofarides A. Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. J Mol Evol. 2020;88(1):26–40. doi:10.1007/s00239-019-09914-331659373
   PubMed Web of Science ®Google Scholar
• World Health Organization. La Resistencia a Los Antimicrobianos. Suiza: World Health Organization; 2019.
   Google Scholar
• O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Government of the United Kingdom; 2016.
   Google Scholar
• Antibiotic/antimicrobial resistance (AR/AMR). Available from: https://www.cdc.gov/drugresistance/index.html. Accessed July 20, 2020.
   Google Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the Eu and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. doi:10.1016/S1473-3099(18)30605-430409683
   PubMed Web of Science ®Google Scholar
• World Health Organization. Superbugs. Why We Need Action Now. World Health Organization; 2016.
   Google Scholar
• Thompson ND, LaPlace L, Epstein L, et al. Prevalence of antimicrobial use and opportunities to improve prescribing practices in U.S. nursing homes. J Am Med Dir Assoc. 2016;17(12):1151–1153. doi:10.1016/j.jamda.2016.08.01327751803
   PubMed Web of Science ®Google Scholar
• Woolhouse M, Waugh C, Perry MR, Nair H. Global disease burden due to antibiotic resistance - state of the evidence. J Glob Health. 2016;6(1):10306. doi:10.7189/jogh.06.010306
   Web of Science ®Google Scholar
• Santhakumari S, Ravi AV, Logalakshmi R. Targeting Quorum sensing mechanism: an alternative anti-virulent strategy for the treatment of bacterial infections. Int J Food Microbiol. 2018;281:60–71. doi:10.1016/j.ijfoodmicro.2018.05.02429864697
   PubMed Web of Science ®Google Scholar
• Gil-Gil T, Laborda P, Sanz-García F, Hernando-Amado S, Blanco P, Martínez JL. Antimicrobial resistance: a multifaceted problem with multipronged solutions. Microbiologyopen. 2019;8(11):e945. doi:10.1002/mbo3.94531724836
   PubMed Web of Science ®Google Scholar
• Xu WC, Silverman MH, Yu XY, Wright G, Brown N. Discovery and development of DNA polymerase iiic inhibitors to treat gram-positive infections. Bioorg Med Chem. 2019;27(15):3209–3217. doi:10.1016/j.bmc.2019.06.01731221610
   PubMed Web of Science ®Google Scholar
• Antibiotic Research UK; 2019. Available from: https://www.antibioticresearch.org.uk/about-antibiotic-resistance. Accessed November 27, 2021.
   Google Scholar
• Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013;56(10):1445–1450. doi:10.1093/cid/cit07023403172
   PubMed Web of Science ®Google Scholar
• DeNegre AA, Ndeffo Mbah ML, Myers K, Fefferman NH. Emergence of antibiotic resistance in immunocompromised host populations: a case study of emerging antibiotic resistant tuberculosis in aids patients. PLoS One. 2019;14(2):e0212969. doi:10.1371/journal.pone.021296930817798
   PubMed Web of Science ®Google Scholar
• Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016;529(7586):336–343. doi:10.1038/nature1704226791724
   PubMed Web of Science ®Google Scholar
• Fairlamb AH, Gow NA, Matthews KR, Waters AP. drug resistance in eukaryotic microorganisms. Nat Microbiol. 2016;1(7):16092. doi:10.1038/nmicrobiol.2016.9227572976
   PubMed Web of Science ®Google Scholar
• Hoenes K, Bauer R, Meurle T, Spellerberg B, Hessling M. Inactivation effect of violet and blue light on eskape pathogens and closely related non-pathogenic bacterial species - a promising tool against antibiotic-sensitive and antibiotic-resistant microorganisms. Front Microbiol. 2020;11:612367. doi:10.3389/fmicb.2020.61236733519770
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no eskape. J Infect Dis. 2008;197(8):1079–1081. doi:10.1086/53345218419525
   PubMed Web of Science ®Google Scholar
• Biggest threats and data. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed March 2, 2021.
   Google Scholar
• Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010;13(6):151–171. doi:10.1016/j.drup.2010.08.00320833577
   PubMed Web of Science ®Google Scholar
• Groves MD, Crouch B, Coombs GW, et al. Molecular epidemiology of methicillin-resistant staphylococcus aureus isolated from Australian veterinarians. PLoS One. 2016;11(1):e0146034. doi:10.1371/journal.pone.014603426735694
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol. 2000;60(4):457–470. doi:10.1016/S0006-2952(00)00291-410874120
   PubMed Web of Science ®Google Scholar
• Bao M, Zhang L, Liu B, et al. Synergistic effects of anti-mrsa herbal extracts combined with antibiotics. Future Microbiol. 2020;15:1265–1276. doi:10.2217/fmb-2020-000133026882
   PubMed Web of Science ®Google Scholar
• Piątkowska E, Piątkowski J, Przondo-Mordarska A. The strongest resistance of Staphylococcus aureus to erythromycin is caused by decreasing uptake of the antibiotic into the cells. Cell Mol Biol Lett. 2012;17(4):633–645. doi:10.2478/s11658-012-0034-323001512
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant staphylococcus aureus containing the vana resistance gene. N Engl J Med. 2003;348(14):1342–1347. doi:10.1056/NEJMoa02502512672861
   PubMed Web of Science ®Google Scholar
• Peraman R, Sure SK, Dusthackeer VNA, et al. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. Futur J Pharm Sci. 2021;7(1):56. doi:10.1186/s43094-021-00196-533686369
   PubMed Web of Science ®Google Scholar
• Ghodhbane H, Elaidi S, Sabatier JM, Achour S, Benhmida J, Regaya I. Bacteriocins active against multi-resistant gram negative bacteria implicated in nosocomial infections. Infect Disord Drug Targets. 2015;15(1):2–12. doi:10.2174/187152651466614052211333724853876
   PubMedGoogle Scholar
• Oliveira J, Reygaert WC. Gram negative bacteria. In: Statpearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
   Google Scholar
• Motbainor H, Bereded F, Mulu W. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and pseudomonas aeruginosa among patients hospitalized at Felegehiwot Referral Hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis. 2020;20(1):92. doi:10.1186/s12879-020-4811-832000693
   PubMed Web of Science ®Google Scholar
• Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in gram-negative bacilli. Ann Intensive Care. 2015;5(1):61. doi:10.1186/s13613-015-0061-026261001
   PubMed Web of Science ®Google Scholar
• Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. J Antibiot (Tokyo). 2014;67(1):7–22. doi:10.1038/ja.2013.4923756684
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x29671219
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-avibactam: a novel cephalosporin/Β-lactamase inhibitor combination for the treatment of resistant gram-negative organisms. Clin Ther. 2016;38(3):431–444. doi:10.1016/j.clinthera.2016.01.01826948862
   PubMed Web of Science ®Google Scholar
• Avycaz FDA highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206494s003lbl.pdf. Accessed March 29, 2018.
   Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (reprise): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673. doi:10.1016/S1473-3099(16)30004-427107460
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380–1389. doi:10.1093/cid/ciw13326962078
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.00931863899
   PubMed Web of Science ®Google Scholar
• Raj G, Priyadarshini R, Murugesan S, Adhimoolam M. Monoclonal antibodies against infectious microbes: so long and too little! infect disord drug targets. Infect Disord Drug Targets. 2020;21(1):4–27.
   Google Scholar
• Henning LN, Carpenter S, Stark GV, Serbina NV. Development of protective immunity in New Zealand white rabbits challenged with bacillus anthracis spores and treated with antibiotics and obiltoxaximab, a monoclonal antibody against protective antigen. Antimicrob Agents Chemother. 2018;62(2). doi:10.1128/AAC.01590-17
   Web of Science ®Google Scholar
• Nagy CF, Leach TS, King A, Guttendorf R. Safety, pharmacokinetics, and immunogenicity of obiltoxaximab after intramuscular administration to healthy humans. Clin Pharmacol Drug Dev. 2018;7(6):652–660. doi:10.1002/cpdd.41029125719
   PubMed Web of Science ®Google Scholar
• Deeks ED. Bezlotoxumab: a review in preventing clostridium difficile infection recurrence. Drugs. 2017;77(15):1657–1663. doi:10.1007/s40265-017-0809-y28865041
   PubMed Web of Science ®Google Scholar
• Johnson S, Gerding DN. Bezlotoxumab. Clin Infect Dis. 2019;68(4):699–704. doi:10.1093/cid/ciy57730020417
   PubMed Web of Science ®Google Scholar
• Shiu J, Ting G, Kiang TK. Clinical pharmacokinetics and pharmacodynamics of delafloxacin. Eur J Drug Metab Pharmacokinet. 2019;44(3):305–317. doi:10.1007/s13318-018-0520-830324277
   PubMed Web of Science ®Google Scholar
• Bassetti M, Pecori D, Cojutti P, Righi E, Pea F. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Drug Metab Toxicol. 2017;13(11):1193–1200. doi:10.1080/17425255.2017.138665428988505
   PubMed Web of Science ®Google Scholar
• Markham A. Delafloxacin: first global approval. Drugs. 2017;77(13):1481–1486. doi:10.1007/s40265-017-0790-528748399
   PubMed Web of Science ®Google Scholar
• Cho JC, Zmarlicka MT, Shaeer KM, Pardo J. Meropenem/vaborbactam, the first carbapenem/β-lactamase inhibitor combination. Ann Pharmacother. 2018;52(8):769–779. doi:10.1177/106002801876328829514462
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/AAC.01443-17
   Web of Science ®Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-Β-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98. doi:10.1007/s40265-017-0851-929230684
   PubMed Web of Science ®Google Scholar
• Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs. 2018;78(12):1259–1270. doi:10.1007/s40265-018-0966-730128699
   PubMed Web of Science ®Google Scholar
• Ozenoxacin. FDA highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf. Accessed March 24, 2018.
   Google Scholar
• Pascale R, Giannella M, Bartoletti M, Viale P, Pea F. Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. Expert Rev Anti Infect Ther. 2019;17(10):819–827. doi:10.1080/14787210.2019.167373131559876
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Stein GE. Plazomicin: a new aminoglycoside. Clin Infect Dis. 2020;70(4):704–709. doi:10.1093/cid/ciz64031328228
   PubMed Web of Science ®Google Scholar
• Zemdri (Plazomicin) FDA highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf. Accessed November 27, 2021.
   Google Scholar
• Hussar DA. New drugs 2019, part 4. Nursing. 2019;49(11):34–43. doi:10.1097/01.NURSE.0000585892.82614.f4
   Google Scholar
• Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections. Drugs. 2019;79(3):243–269. doi:10.1007/s40265-019-1054-330723876
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567–588. doi:10.1007/s40265-016-0545-826863149
   PubMed Web of Science ®Google Scholar
• Scott LJ. Eravacycline: a review in complicated intra-abdominal infections. Drugs. 2019;79(3):315–324. doi:10.1007/s40265-019-01067-330783960
   PubMed Web of Science ®Google Scholar
• Heaney M, Mahoney MV, Gallagher JC. Eravacycline: the tetracyclines strike back. Ann Pharmacother. 2019;53(11):1124–1135. doi:10.1177/106002801985017331081341
   PubMed Web of Science ®Google Scholar
• Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019;38(10):1787–1794. doi:10.1007/s10096-019-03590-331175478
   PubMed Web of Science ®Google Scholar
• Moore AY, Del Rosso J, Johnson JL, Grada A. Sarecycline: a review of preclinical and clinical evidence. Clin Cosmet Investig Dermatol. 2020;13:553–560. doi:10.2147/CCID.S190473
   Web of Science ®Google Scholar
• Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235–1242. doi:10.2217/fmb-2019-019931475868
   PubMed Web of Science ®Google Scholar
• Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Sarecycline review. Ann Pharmacother. 2020;54(2):164–170. doi:10.1177/106002801987311131462063
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Burgos RM, Tan X, Pai MP. Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2020;59(4):409–425. doi:10.1007/s40262-019-00843-431773505
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Omadacycline: a modernized tetracycline. Clin Infect Dis. 2019;69(Suppl 1):S1–s5. doi:10.1093/cid/ciz39431367739
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80(3):285–313. doi:10.1007/s40265-020-01257-431970713
   PubMed Web of Science ®Google Scholar
• Riddle MS, Connor P, Tribble DR. Antibiotics for travellers’ diarrhoea on trial-is there a potential role for rifamycin SV? J Travel Med. 2019;26(1). doi:10.1093/jtm/tay137
   Web of Science ®Google Scholar
• US Food & Drug Administration; 2018. FDA approves new drug to treat travelers’ diarrhea. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626121.htm. Accessed November 16, 2018.
   Google Scholar
• Hoy SM. Rifamycin SV MMX(®): a review in the treatment of traveller’s diarrhoea. Clin Drug Investig. 2019;39(7):691–697. doi:10.1007/s40261-019-00808-2
   PubMed Web of Science ®Google Scholar
• Ghazi IM, El Nekidy WS, Asay R, Fimognari P, Knarr A, Awad M. Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach. PLoS One. 2020;15(5):e0233335. doi:10.1371/journal.pone.023333532421696
   PubMed Web of Science ®Google Scholar
• Thakare R, Dasgupta A, Chopra S. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections. Drugs Today (Barc). 2020;56(4):241–255. doi:10.1358/dot.2020.56.4.307579632309820
   PubMed Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60(10):6234–6243. doi:10.1128/AAC.00633-1627503659
   PubMed Web of Science ®Google Scholar
• Singh R, Manjunatha U, Boshoff HI, et al. Pa-824 kills nonreplicating mycobacterium tuberculosis by intracellular no release. Science. 2008;322(5906):1392–1395. doi:10.1126/science.116457119039139
   PubMed Web of Science ®Google Scholar
• Pretomanid tablets: us prescribing information. Available from: https://www.fda.gov/. Accessed August 27, 2019.
   Google Scholar
• Conradie A, Everitt D, Mendel C, et al. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid [Abstract No. Oa03-213-25 and presentation]. Int J Tuberc Lung Dis. 2018;22(Suppl.2):S69.
   Google Scholar
• Keam SJ. Pretomanid: first approval. Drugs. 2019;79(16):1797–1803. doi:10.1007/s40265-019-01207-931583606
   PubMed Web of Science ®Google Scholar
• El-Lababidi RM, Rizk JG. Cefiderocol: a siderophore cephalosporin. Ann Pharmacother. 2020;54(12):1215–1231. doi:10.1177/106002802092998832522005
   PubMed Web of Science ®Google Scholar
• FDA Fetroja (Cefiderocol) for injection, for intravenous use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf. Accessed November 14, 2019.
   Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271–289. doi:10.1007/s40265-019-1055-230712199
   PubMed Web of Science ®Google Scholar
• Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Investig Drugs. 2018;27(2):193–197. doi:10.1080/13543784.2018.1426745
   PubMed Web of Science ®Google Scholar
• Tang HJ, Wang JH, Lai CC. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia. Medicine (Baltimore). 2020;99(29):e21223. doi:10.1097/MD.000000000002122332702892
   PubMed Web of Science ®Google Scholar
• Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018;38(9):935–946. doi:10.1002/phar.216630019769
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Deng C, Zelenitsky S, et al. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 2021;81(2):233–256. doi:10.1007/s40265-020-01443-4
   Google Scholar
• Koulenti D, Song A, Ellingboe A, et al. Infections by multidrug-resistant gram-negative bacteria: what’s new in our arsenal and what’s in the pipeline? Int J Antimicrob Agents. 2019;53(3):211–224. doi:10.1016/j.ijantimicag.2018.10.01130394301
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Meunier D, et al. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother. 2017;72(8):2278–2289. doi:10.1093/jac/dkx13628520867
   PubMed Web of Science ®Google Scholar
• Seifert H, Körber-Irrgang B, Kresken M. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Int J Antimicrob Agents. 2018;51(2):227–234. doi:10.1016/j.ijantimicag.2017.06.02428705666
   PubMed Web of Science ®Google Scholar
• Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. Ceftolozane-tazobactam: a new-generation cephalosporin. Am J Health Syst Pharm. 2015;72(24):2135–2146. doi:10.2146/ajhp15004926637512
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (Minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015). Int J Antimicrob Agents. 2018;51(2):181–189. doi:10.1016/j.ijantimicag.2017.09.01628993143
   PubMed Web of Science ®Google Scholar
• Livermore DM, Meunier D, Hopkins KL, et al. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16. J Antimicrob Chemother. 2018;73(3):648–657. doi:10.1093/jac/dkx43829228202
   PubMed Web of Science ®Google Scholar
• Bassetti M, Labate L, Vena A, Giacobbe DR. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. Curr Opin Infect Dis. 2021;34(2):96–108. doi:10.1097/QCO.000000000000071433405480
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, Li Y, Cai Y. Efficacy and safety of dalbavancin in the treatment of gram-positive bacterial infections. J Glob Antimicrob Resist. 2020;24:72–80. doi:10.1016/j.jgar.2020.11.01833279683
   PubMed Web of Science ®Google Scholar
• Bongiorno D, Lazzaro LM, Stefani S, Campanile F. In vitro activity of dalbavancin against refractory multidrug-resistant (MDR) Staphylococcus aureus isolates. Antibiotics (Basel). 2020;9(12). doi:10.3390/antibiotics9120865
   Web of Science ®Google Scholar
• Zahornacký O, Novotný M. [Dalbavancin and its use in the treatment of methicillin-resistant Staphylococcus aureus - induced upper limb phlegmon]. Klin Mikrobiol Infekc Lek. 2020;26(2):51–53. Slovak.33389741
   PubMedGoogle Scholar
• Meyer J, Lata P, Barnett S. Continued dosing of oritavancin for complicated gram-positive infections. Fed Pract. 2020;37(11):502–504. doi:10.12788/fp.006833328715
   PubMedGoogle Scholar
• Dretske D, Schulz L, Werner E, Sharp B, Pulia M. Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: a case series. Am J Emerg Med. 2021;43:77–80. doi:10.1016/j.ajem.2021.01.05033545550
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration; 2021. Antimicrobial resistance information from FDA. Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance-information-fda#top. Accessed November 24, 2021.
   Google Scholar
• Brownell LE, Adamsick ML, McCreary EK, et al. Clinical outcomes and economic impact of oritavancin for gram-positive infections: a single academic medical center health system experience. Drugs Real World Outcomes. 2020;7(Suppl 1):13–19. doi:10.1007/s40801-020-00192-w32592120
   PubMedGoogle Scholar
• Melinta Therapeutics LLC; 2021.Kimyrsa™ (Oritavancin) for injection [Prescribing information]. Available from: https://melintamedicalinformation.com/Media/PI/KIMYRSA%20Prescribing%20Information%2007%202021.pdf. Accessed July 29, 2018.
   Google Scholar
• Loza E, Sarciaux M, Ikaunieks M, et al. Structure-activity relationship studies on the inhibition of the bacterial translation of novel odilorhabdins analogues. Bioorg Med Chem. 2020;28(11):115469. doi:10.1016/j.bmc.2020.11546932279921
   PubMed Web of Science ®Google Scholar
• Racine E, Gualtieri M. From worms to drug candidate: the story of odilorhabdins, a new class of antimicrobial agents. Front Microbiol. 2019;10:2893. doi:10.3389/fmicb.2019.0289331921069
   PubMed Web of Science ®Google Scholar
• Pantel L, Florin T, Dobosz-Bartoszek M, et al. Odilorhabdins, antibacterial agents that cause miscoding by binding at a new ribosomal site. Mol Cell. 2018;70(1):83–94.e87. doi:10.1016/j.molcel.2018.03.00129625040
   PubMed Web of Science ®Google Scholar
• Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25(6):1340. doi:10.3390/molecules25061340
   PubMed Web of Science ®Google Scholar
• Jin K, Po KHL, Wang S, et al. Synthesis and structure-activity relationship of teixobactin analogues via convergent Ser Ligation. Bioorg Med Chem. 2017;25(18):4990–4995. doi:10.1016/j.bmc.2017.04.03928495382
   PubMed Web of Science ®Google Scholar
• Guo C, Mandalapu D, Ji X, Gao J, Zhang Q. Chemistry and biology of teixobactin. Chemistry. 2018;24(21):5406–5422. doi:10.1002/chem.20170416728991382
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu Y, Chan-Park MB, Mu Y. Binding modes of teixobactin to lipid II: molecular dynamics study. Sci Rep. 2017;7(1):17197. doi:10.1038/s41598-017-17606-529222455
   PubMed Web of Science ®Google Scholar
• Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455–459. doi:10.1038/nature1409825561178
   PubMed Web of Science ®Google Scholar
• Huanyun Z, Ruijuan L. Research progress of a new antibiotic teixobactin that is not easy to induce resistance. Chin J Antibiot. 2019;44(01):9–17.
   Google Scholar
• Jin K, Sam IH, Po KHL, et al. Total synthesis of teixobactin. Nat Commun. 2016;7:12394. doi:10.1038/ncomms1239427484680
   PubMed Web of Science ®Google Scholar
• Giltrap AM, Dowman LJ, Nagalingam G, et al. Total synthesis of teixobactin. Org Lett. 2016;18(11):2788–2791. doi:10.1021/acs.orglett.6b0132427191730
   PubMed Web of Science ®Google Scholar
• Parmar A, Lakshminarayanan R, Iyer A, et al. Design and syntheses of highly potent teixobactin analogues against Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant enterococci (VRE) in vitro and in vivo. J Med Chem. 2018;61(5):2009–2017. doi:10.1021/acs.jmedchem.7b0163429363971
   PubMed Web of Science ®Google Scholar
• Liu J, Smith PA, Steed DB, Romesberg F. Efforts toward broadening the spectrum of arylomycin antibiotic activity. Bioorg Med Chem Lett. 2013;23(20):5654–5659. doi:10.1016/j.bmcl.2013.08.02624012184
   PubMed Web of Science ®Google Scholar
• Smith PA, Koehler MFT, Girgis HS, et al. Optimized arylomycins are a new class of gram-negative antibiotics. Nature. 2018;561(7722):189–194. doi:10.1038/s41586-018-0483-630209367
   PubMed Web of Science ®Google Scholar
• Lam YC, Crawford JM. Discovering antibiotics from the global microbiome. Nat Microbiol. 2018;3(4):392–393. doi:10.1038/s41564-018-0135-529588534
   PubMed Web of Science ®Google Scholar
• Kleijn LH, Oppedijk SF, Hart P, et al. Total synthesis of laspartomycin C and characterization of its antibacterial mechanism of action. J Med Chem. 2016;59(7):3569–3574. doi:10.1021/acs.jmedchem.6b0021926967152
   PubMed Web of Science ®Google Scholar
• Hover BM, Kim SH, Katz M, et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant gram-positive pathogens. Nat Microbiol. 2018;3(4):415–422. doi:10.1038/s41564-018-0110-129434326
   PubMed Web of Science ®Google Scholar
• Hart EM, Mitchell AM, Konovalova A, et al. A small-molecule inhibitor of bama impervious to efflux and the outer membrane permeability barrier. Proc Natl Acad Sci U S A. 2019;116(43):21748–21757. doi:10.1073/pnas.191234511631591200
   PubMed Web of Science ®Google Scholar
• Imai Y, Meyer KJ, Iinishi A, et al. A new antibiotic selectively kills gram-negative pathogens. Nature. 2019;576(7787):459–464. doi:10.1038/s41586-019-1791-131747680
   PubMed Web of Science ®Google Scholar
• Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e613. doi:10.1016/j.cell.2020.01.02132084340
   PubMed Web of Science ®Google Scholar
• Stokes JM, Gutierrez A, Lopatkin AJ, et al. A multiplexable assay for screening antibiotic lethality against drug-tolerant bacteria. Nat Methods. 2019;16(4):303–306. doi:10.1038/s41592-019-0333-y30858599
   PubMed Web of Science ®Google Scholar
• Balaban NQ, Helaine S, Lewis K, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17(7):441–448. doi:10.1038/s41579-019-0196-330980069
   PubMed Web of Science ®Google Scholar
• Böhringer N, Patras MA, Schäberle TF. Heterologous expression of pseudouridimycin and description of the corresponding minimal biosynthetic gene cluster. Molecules. 2021;26(2):510. doi:10.3390/molecules2602051033478059
   PubMed Web of Science ®Google Scholar
• Chellat MF, Riedl R. Pseudouridimycin: the first nucleoside analogue that selectively inhibits bacterial RNA polymerase. Angew Chem Int Ed Engl. 2017;56(43):13184–13186. doi:10.1002/anie.20170813328895263
   PubMed Web of Science ®Google Scholar
• O’Malley PA. Pseudouridimycin: light in the darkness of antimicrobial resistance. Clin Nurse Spec. 2018;32(3):114–115. doi:10.1097/NUR.000000000000036729621104
   PubMed Web of Science ®Google Scholar
• Maffioli SI, Zhang Y, Degen D, et al. Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase. Cell. 2017;169(7):1240–1248.e1223. doi:10.1016/j.cell.2017.05.04228622509
   PubMed Web of Science ®Google Scholar
• Krasavin M, Trifonov RE, Tolstyakov VV, et al. 5-methyl-7-(3-Nitro-[1,2,4]Triazol-1-Yl)-[1,2,4]Triazolo[1,5-a]Pyrimidine, having anti-tuberculosis activity against the agent with multiple drug resistance, and a method for production thereof. Chem. 2019;171:563769.
   Google Scholar
• Chuprun S, Dar’in D, Rogacheva E, et al. Mutually isomeric 2- and 4-(3-Nitro-1,2,4-Triazol-1-Yl)pyrimidines inspired by an antimycobacterial screening hit: synthesis and biological activity against the eskape panel of pathogens. Antibiotics (Basel). 2020;9(10). doi:10.3390/antibiotics9100666
   Web of Science ®Google Scholar
• Deming Z, Taiping H, Sanqi Z, Ningren J. Synthesis process optimization of methoxycephalosporin intermediate 7-amca. Guangzhou Chem Indust. 2009;37(09):80–83.
   Google Scholar
• Yan R, Ning J, Yuan W. (6s) or (7s)-methoxy Β-lactam antibiotics. Foreign Med. 2007;6:252–258+276.
   Google Scholar
• Shaohua L, Wei W, Zengying H, Hongming L, Shenghua C, Xiaodong D. Improvement of synthesis process of methoxef intermediate 7-MAC. Chem Res Appl. 2013;25(04):547–549.
   Google Scholar
• Kuailin S, Runsun L, Xinghan L. Studies on Β-lactam antibiotics——II. Synthesis of 7-substituted azide cephalosporins and 7α-methoxy-7β substituted hydrazone cephalosporins. Antibiotics. 1985;3:165–166.
   Google Scholar
• Lili T, Li W, Jiaxin L, Dacheng W, Feng G, Lin W. Evaluation of the antibacterial activity of a new cephalosporin compound NAC-3 and its in vivo protection against MRSA infections. Chin J Vet Med. 2020;40(08):1571–1578.
   Google Scholar
• Serafim MSM, Lavorato SN, Kronenberger T, et al. Antibacterial activity of synthetic 1,3-Bis(Aryloxy)propan-2-amines against gram-positive bacteria. Microbiologyopen. 2019;8(11):e814. doi:10.1002/mbo3.81430773849
   PubMed Web of Science ®Google Scholar
• Barman S, Konai MM, Samaddar S, Haldar J. Amino acid conjugated polymers: antibacterial agents effective against drug-resistant Acinetobacter baumannii with no detectable resistance. ACS Appl Mater Interfaces. 2019;11(37):33559–33572. doi:10.1021/acsami.9b0901631424189
   PubMed Web of Science ®Google Scholar
• Mukherjee I, Ghosh A, Bhadury P, De P. Side-chain amino acid-based cationic antibacterial polymers: investigating the morphological switching of a polymer-treated bacterial cell. ACS Omega. 2017;2(4):1633–1644. doi:10.1021/acsomega.7b0018130023640
   PubMed Web of Science ®Google Scholar
• Jean SS, Gould IM, Lee WS, Hsueh PR. New drugs for multidrug-resistant gram-negative organisms: time for stewardship. Drugs. 2019;79(7):705–714. doi:10.1007/s40265-019-01112-130972660
   PubMed Web of Science ®Google Scholar
• Hamrick JC, Docquier JD, Uehara T, et al. Vnrx-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-Β-lactamases, restores activity of cefepime in enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2020;64(3). doi:10.1128/AAC.01963-19
   Web of Science ®Google Scholar
• Wang X, Zhao C, Wang Q, et al. In vitro activity of the novel Β-lactamase inhibitor taniborbactam (Vnrx-5133), in combination with cefepime or meropenem, against MDR gram-negative bacterial isolates from China. J Antimicrob Chemother. 2020;75(7):1850–1858. doi:10.1093/jac/dkaa05332154866
   PubMed Web of Science ®Google Scholar
• Thwaites M, Hall D, Stoneburner A, et al. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2018;92(4):338–345. doi:10.1016/j.diagmicrobio.2018.07.00630097297
   PubMed Web of Science ®Google Scholar
• Procópio TF, Moura MC, Bento EFL, et al. Looking for alternative treatments for bovine and caprine mastitis: evaluation of the potential of Calliandra surinamensis leaf pinnulae lectin (Casul), both alone and in combination with antibiotics. Microbiologyopen. 2019;8(11):e869. doi:10.1002/mbo3.86931099495
   PubMed Web of Science ®Google Scholar
• Breidenstein EB, de la Fuente-núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419–426. doi:10.1016/j.tim.2011.04.00521664819
   PubMed Web of Science ®Google Scholar
• Yang X, Goswami S, Gorityala BK, et al. A tobramycin vector enhances synergy and efficacy of efflux pump inhibitors against multidrug-resistant gram-negative bacteria. J Med Chem. 2017;60(9):3913–3932. doi:10.1021/acs.jmedchem.7b0015628399372
   PubMed Web of Science ®Google Scholar
• Kalan L, Wright GD. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Rev Mol Med. 2011;13:e5. doi:10.1017/S146239941000176621342612
   PubMed Web of Science ®Google Scholar
• Brown D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat Rev Drug Discov. 2015;14(12):821–832. doi:10.1038/nrd467526493767
   PubMed Web of Science ®Google Scholar
• Gill EE, Franco OL, Hancock RE. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des. 2015;85(1):56–78. doi:10.1111/cbdd.1247825393203
   PubMed Web of Science ®Google Scholar
• Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013;66(10):571–591. doi:10.1038/ja.2013.8624002361
   PubMed Web of Science ®Google Scholar
• Bagińska N, Pichlak A, Górski A, Jończyk-Matysiak E. Specific and selective bacteriophages in the fight against multidrug-resistant Acinetobacter baumannii. Virol Sin. 2019;34(4):347–357. doi:10.1007/s12250-019-00125-031093881
   PubMed Web of Science ®Google Scholar
• Gordillo Altamirano F, Forsyth JH, Patwa R, et al. Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat Microbiol. 2021;6(2):157–161. doi:10.1038/s41564-020-00830-733432151
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Boukovalas S, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother. 2011;55(5):2395–2397. doi:10.1128/AAC.01086-1021321144
   PubMed Web of Science ®Google Scholar
• Williams PC. Potential of fosfomycin in treating multidrug-resistant infections in children. J Paediatr Child Health. 2020;56(6):864–872. doi:10.1111/jpc.1488332294306
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Van Bambeke F, Cantón R, et al. Reviving old antibiotics. J Antimicrob Chemother. 2015;70(8):2177–2181. doi:10.1093/jac/dkv15726063727
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Falci DR, Zavascki AP. Clinical use of polymyxin B. Adv Exp Med Biol. 2019;1145:197–218.31364080
   PubMed Web of Science ®Google Scholar
• Garg SK, Singh O, Juneja D, et al. Resurgence of polymyxin B for MDR/XDR gram-negative infections: an overview of current evidence. Crit Care Res Pract. 2017;2017:3635609. doi:10.1155/2017/363560928761764
   PubMedGoogle Scholar
• Hortle E, Johnson KE, Johansen MD, et al. Thrombocyte inhibition restores protective immunity to mycobacterial infection in zebrafish. J Infect Dis. 2019;220(3):524–534. doi:10.1093/infdis/jiz11030877311
   PubMed Web of Science ®Google Scholar
• Pribis JP, García-Villada L, Zhai Y, et al. Gamblers: an antibiotic-induced evolvable cell subpopulation differentiated by reactive-oxygen-induced general stress response. Mol Cell. 2019;74(4):785–800.e787. doi:10.1016/j.molcel.2019.02.03730948267
   PubMed Web of Science ®Google Scholar
• Guachalla LM, Stojkovic K, Hartl K, et al. Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. Pneumoniae O3 Sci Rep. 2017;7(1):6635. doi:10.1038/s41598-017-06682-228747785
   PubMed Web of Science ®Google Scholar
• Rollenske T, Szijarto V, Lukasiewicz J, et al. Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen. Nat Immunol. 2018;19(6):617–624. doi:10.1038/s41590-018-0106-229760533
   PubMed Web of Science ®Google Scholar
• Förster B, Chung PK, Crobach MJT, Kuijper EJ. Application of antibody-mediated therapy for treatment and prevention of clostridium difficile infection. Front Microbiol. 2018;9:1382. doi:10.3389/fmicb.2018.0138229988597
   PubMed Web of Science ®Google Scholar
• Helbig ET, Opitz B, Sander LE. Adjuvant immunotherapies as a novel approach to bacterial infections. Immunotherapy. 2013;5(4):365–381. doi:10.2217/imt.13.1723557420
   PubMed Web of Science ®Google Scholar
• Akbari R, Hakemi Vala M, Hashemi A, Aghazadeh H, Sabatier JM, Pooshang Bagheri K. Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug resistant bacteria. Amino Acids. 2018;50(9):1231–1243. doi:10.1007/s00726-018-2596-529905903
   PubMed Web of Science ®Google Scholar
• Di YP, Lin Q, Chen C, Montelaro RC, Doi Y, Deslouches B. Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. Sci Adv. 2020;6(18):eaay6817. doi:10.1126/sciadv.aay681732426473
   PubMed Web of Science ®Google Scholar
• Khara JS, Obuobi S, Wang Y, et al. Disruption of drug-resistant biofilms using de novo designed short Α-helical antimicrobial peptides with idealized facial amphiphilicity. Acta Biomater. 2017;57:103–114. doi:10.1016/j.actbio.2017.04.03228457962
   PubMed Web of Science ®Google Scholar
• Li SA, Lee WH, Zhang Y. Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models. Antimicrob Agents Chemother. 2012;56(6):3309–3317. doi:10.1128/AAC.06304-1122491685
   PubMed Web of Science ®Google Scholar
• Zhao F, Lan XQ, Du Y, et al. King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates. Zool Res. 2018;39(2):87–96. doi:10.24272/j.issn.2095-8137.2018.02529515090
   PubMed Web of Science ®Google Scholar
• Sun H, Wei C, Liu B, et al. Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine. Int J Nanomedicine. 2015;10:7275–7290. doi:10.2147/IJN.S9152926664118
   PubMed Web of Science ®Google Scholar
• Pierpaoli E, Orlando F, Cirioni O, Simonetti O, Giacometti A, Provinciali M. Supplementation with tocotrienols from bixa orellana improves the in vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of infected wound. Phytomedicine. 2017;36:50–53. doi:10.1016/j.phymed.2017.09.01129157827
   PubMed Web of Science ®Google Scholar
• Mayaud L, Carricajo A, Zhiri A, Aubert G. Comparison of bacteriostatic and bactericidal activity of 13 essential oils against strains with varying sensitivity to antibiotics. Lett Appl Microbiol. 2008;47(3):167–173. doi:10.1111/j.1472-765X.2008.02406.x19552780
   PubMed Web of Science ®Google Scholar
• Brehm-Stecher BF, Johnson EA. Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob Agents Chemother. 2003;47(10):3357–3360. doi:10.1128/AAC.47.10.3357-3360.200314506058
   PubMed Web of Science ®Google Scholar
• Swamy MK, Akhtar MS, Sinniah UR. Antimicrobial properties of plant essential oils against human pathogens and their mode of action: an updated review. Evid Based Complement Alternat Med. 2016;2016:3012462. doi:10.1155/2016/301246228090211
   PubMed Web of Science ®Google Scholar
• Süntar I, Akkol EK, Keleş H, et al. Healing ointment: a formulation of hypericum perforatum oil and sage and oregano essential oils based on traditional Turkish knowledge. J Ethnopharmacol. 2011;134(1):89–96. doi:10.1016/j.jep.2010.11.06121130859
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xie M, Song Y, et al. Two traditional Chinese medicines curcumae radix and curcumae rhizoma: an ethnopharmacology, phytochemistry, and pharmacology review. Evid Based Complement Alternat Med. 2016;2016:4973128. doi:10.1155/2016/497312827057197
   PubMed Web of Science ®Google Scholar
• Tariq S, Wani S, Rasool W, et al. A comprehensive review of the antibacterial, antifungal and antiviral potential of essential oils and their chemical constituents against drug-resistant microbial pathogens. Microb Pathog. 2019;134:103580. doi:10.1016/j.micpath.2019.10358031195112
   PubMed Web of Science ®Google Scholar
• Yap PS, Yiap BC, Ping HC, Lim SH. Essential oils, a new horizon in combating bacterial antibiotic resistance. Open Microbiol J. 2014;8:6–14. doi:10.2174/187428580140801000624627729
   PubMedGoogle Scholar
• Lahmar A, Bedoui A, Mokdad-Bzeouich I, et al. Reversal of resistance in bacteria underlies synergistic effect of essential oils with conventional antibiotics. Microb Pathog. 2017;106:50–59. doi:10.1016/j.micpath.2016.10.01827815129
   PubMed Web of Science ®Google Scholar
• Solórzano-Santos F, Miranda-Novales MG. Essential oils from aromatic herbs as antimicrobial agents. Curr Opin Biotechnol. 2012;23(2):136–141. doi:10.1016/j.copbio.2011.08.00521903378
   PubMed Web of Science ®Google Scholar
• Yu Z, Tang J, Khare T, Kumar V. The alarming antimicrobial resistance in ESKAPEE pathogens: can essential oils come to the rescue? Fitoterapia. 2020;140:104433. doi:10.1016/j.fitote.2019.10443331760066
   PubMed Web of Science ®Google Scholar
• Oliva A, Costantini S, De Angelis M, et al. High potency of melaleuca alternifolia essential oil against multi-drug resistant gram-negative bacteria and methicillin-resistant Staphylococcus aureus. Molecules. 2018;23(10):2584. doi:10.3390/molecules23102584
   Web of Science ®Google Scholar
• Marchitto MC, Dillen CA, Liu H, et al. Clonal Vγ6(+)Vδ4(+) T cells promote Il-17-mediated immunity against Staphylococcus aureus skin infection. Proc Natl Acad Sci U S A. 2019;116(22):10917–10926. doi:10.1073/pnas.181825611631088972
   PubMed Web of Science ®Google Scholar
• Raz A, Serrano A, Lawson C, et al. Lysibodies Are Igg Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis. Proc Natl Acad Sci U S A. 2017;114(18):4781–4786. doi:10.1073/pnas.161924911428428342
   PubMed Web of Science ®Google Scholar
• Raz A, Serrano A, Thaker M, Alston T, Fischetti VA. Lysostaphin lysibody leads to effective opsonization and killing of methicillin-resistant Staphylococcus aureus in a murine model. Antimicrob Agents Chemother. 2018;62(10). doi:10.1128/AAC.01056-18
   Web of Science ®Google Scholar
• Kalia VC, Wood TK, Kumar P. Evolution of resistance to quorum-sensing inhibitors. Microb Ecol. 2014;68(1):13–23. doi:10.1007/s00248-013-0316-y24194099
   PubMed Web of Science ®Google Scholar
• Tonkin M, Khan S, Wani MY, Ahmad A. Quorum sensing - a stratagem for conquering multi-drug resistant pathogens. Curr Pharm Des. 2020. doi:10.2174/1381612826666201210105638
   Web of Science ®Google Scholar
• Shaaban M, Elgaml A, Habib EE. Biotechnological applications of quorum sensing inhibition as novel therapeutic strategies for multidrug resistant pathogens. Microb Pathog. 2019;127:138–143. doi:10.1016/j.micpath.2018.11.04330503958
   PubMed Web of Science ®Google Scholar
• Kumar M, Saxena M, Saxena AK, Nandi S. Recent breakthroughs in various antimicrobial resistance induced quorum sensing biosynthetic pathway mediated targets and design of their inhibitors. Comb Chem High Throughput Screen. 2020;23(6):458–476. doi:10.2174/138620732366620042520580832334498
   PubMed Web of Science ®Google Scholar
• Hu Y, Kwan BW, Osbourne DO, Benedik MJ, Wood TK. Toxin YafQ increases persister cell formation by reducing indole signalling. Environ Microbiol. 2015;17(4):1275–1285. doi:10.1111/1462-2920.1256725041421
   PubMed Web of Science ®Google Scholar
• Wang Y, Tian T, Zhang J, et al. Indole reverses intrinsic antibiotic resistance by activating a novel dual-function importer. mBio. 2019;10(3). doi:10.1128/mBio.00676-19
   Web of Science ®Google Scholar
• Brix A, Cafora M, Aureli M, Pistocchi A. Animal models to translate phage therapy to human medicine. Int J Mol Sci. 2020;21(10):3715. doi:10.3390/ijms21103715
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Development of phage lysins as novel therapeutics: a historical perspective. Viruses. 2018;10(6):310. doi:10.3390/v10060310
   PubMed Web of Science ®Google Scholar
• Jeon J, Park JH, Yong D. Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol. 2019;19(1):70. doi:10.1186/s12866-019-1443-530940074
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani I, Souli M, Giamarellou H. Novel Β-lactam-Β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15(2):133–149. doi:10.1080/17425255.2019.156307130626244
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11(12):1219–1236. doi:10.1080/17512433.2018.154948730444147
   PubMed Web of Science ®Google Scholar
• Han JW, Choi GJ, Kim BS. Antimicrobial aromatic polyketides: a review of their antimicrobial properties and potential use in plant disease control. World J Microbiol Biotechnol. 2018;34(11):163. doi:10.1007/s11274-018-2546-030368604
   PubMed Web of Science ®Google Scholar
• Chen J, Li X, Li L, et al. Coagulation factors Vii, Ix and X are effective antibacterial proteins against drug-resistant gram-negative bacteria. Cell Res. 2019;29(9):711–724. doi:10.1038/s41422-019-0202-331399697
   PubMed Web of Science ®Google Scholar
• Li C, You X. Coagulation factors: a novel class of endogenous host antimicrobial proteins against drug-resistant gram-negative bacteria. Signal Transduct Target Ther. 2019;4:46. doi:10.1038/s41392-019-0083-431728211
   PubMed Web of Science ®Google Scholar
• Hegeto LA, Caleffi-Ferracioli KR, Perez de Souza J, et al. Promising antituberculosis activity of piperine combined with antimicrobials: a systematic review. Microb Drug Resist. 2019;25(1):120–126. doi:10.1089/mdr.2018.010730096263
   PubMed Web of Science ®Google Scholar
• Orenstein R, Patron RL, Seville MT. Why does clostridium difficile infection recur? J Am Osteopath Assoc. 2019;119(5):322–326. doi:10.7556/jaoa.2019.05431034070
   PubMed Web of Science ®Google Scholar
• Dieltjens L, Appermans K, Lissens M, et al. Inhibiting bacterial cooperation is an evolutionarily robust anti-biofilm strategy. Nat Commun. 2020;11(1):107. doi:10.1038/s41467-019-13660-x31919364
   PubMed Web of Science ®Google Scholar
• Hayhurst EJ, Kailas L, Hobbs JK, Foster SJ. Cell wall peptidoglycan architecture in bacillus subtilis. Proc Natl Acad Sci U S A. 2008;105(38):14603–14608. doi:10.1073/pnas.080413810518784364
   PubMed Web of Science ®Google Scholar
• Turner RD, Ratcliffe EC, Wheeler R, Golestanian R, Hobbs JK, Foster SJ. Peptidoglycan architecture can specify division planes in Staphylococcus aureus. Nat Commun. 2010;1:26. doi:10.1038/ncomms102520975691
   PubMed Web of Science ®Google Scholar
• Pasquina-Lemonche L, Burns J, Turner RD, et al. The architecture of the gram-positive bacterial cell wall. Nature. 2020;582(7811):294–297. doi:10.1038/s41586-020-2236-632523118
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services; Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States; 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed March 2, 2021.
   Google Scholar